Mesoblast Limited
Mesoblast Ltd is a biopharmaceutical company focused on developing and commercializing allogeneic cell therapies based on mesenchymal stromal cells. It operates through a global structure with locations in Australia, the United States, and Singapore, and it markets or partners around selected major regions including Japan, Europe, and China.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueApproved or marketed cellular medicines sold directly in covered markets.
Revenue received from partnered products and license arrangements.
Development-stage regenerative medicine programs for future commercialization.
Industrial-scale cell therapy manufacturing capability and related technology.
Customers
Mesoblast sells to healthcare systems and providers that administer its cell therapies, while partnered markets depend on commercial distributors and licensees. The end users are patients with inflammatory, cardiovascular, and pain-related diseases, but reimbursement and hospital adoption are critical to commercialization.
They buy or administer cell therapies for eligible patients in specialist care settings.
They commercialize Mesoblast products in markets such as Japan, Europe, and China.
They determine access and adoption by covering high-cost specialty therapies.
They prescribe therapies for inflammatory, cardiovascular, and pain indications.
Strategy
Mesoblast’s strategy centers on advancing proprietary cell therapy programs into commercialization while protecting the platform with a large patent estate. A second priority is using global partnerships and industrial-scale manufacturing to broaden market access and support delivery of off-the-shelf cellular medicines.
Revenue depends on converting clinical and regulatory progress into marketable products.
Partners extend market access and reduce the need to build direct sales everywhere.
Patent coverage supports pricing power and helps protect the platform from competition.
Industrial-scale off-the-shelf production is central to commercial supply and consistency.
Geography
Mesoblast has operating locations in Australia, the United States, and Singapore, reflecting a cross-border development and manufacturing footprint. Commercial partnerships in Japan, Europe, and China extend its market reach beyond its own direct sales base and are important for accessing larger specialty-pharma markets.
Risks
Mesoblast depends on clinical, regulatory, reimbursement, and manufacturing execution to turn cell therapy programs into durable products. Its business is also exposed to patent disputes, partner dependence, and the possibility that competing therapies or slower-than-expected uptake could limit adoption.
- Reimbursement and market access riskImpact: HighLikelihood: High
Specialty biologics require payer coverage and hospital adoption to scale sales.
Exposure: United States and international markets
- Clinical and regulatory riskImpact: HighLikelihood: Medium
Cell therapies must satisfy safety and efficacy requirements before broad commercialization.
Exposure: Ryoncil and Rexlemestrocel-L development and commercialization
- Manufacturing and quality riskImpact: HighLikelihood: Medium
Off-the-shelf cell medicines require reproducible large-scale manufacturing and release criteria.
Exposure: Cryopreserved cellular medicines
- Intellectual property riskImpact: HighLikelihood: Medium
Patent enforcement and freedom-to-operate are central to the platform's commercial value.
Exposure: Global patent portfolio through at least 2044
- Partner concentration riskImpact: MediumLikelihood: Medium
Commercial partnerships drive access in several major markets and depend on counterparties' execution.
Exposure
Accounting
Judgemental itemsProduct sales and royalty revenue have different economics and timing, affecting growth quality.
Impact: Direct sales and partner royalties may behave differently across periods
Contingent consideration and warrant liabilities are marked to market and can create volatility.
Impact: Non-cash gains or losses may distort operating performance
Amortization of currently marketed intangible assets is included in cost of revenues.
Impact: Affects gross margin and product-level profitability
Development spending is expensed as incurred unless specific capitalization criteria are met.
Impact: Drives reported losses and period comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
BriaCell Therapeutics Corp.
BCTX · Pharmaceutical Preparations
FibroBiologics, Inc.
FBLG · Pharmaceutical Preparations
Last updated: 28/09/2026